R J Flick1, M H Kim2, K Simon3, A Munthali4, M C Hosseinipour5, N E Rosenberg6, P N Kazembe2, J Mpunga7, S Ahmed2. 1. Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi; University of North Carolina Project-Malawi, Lilongwe, Malawi; University of Colorado School of Medicine, Denver, Colorado, USA. 2. Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi; Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA. 3. Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA. 4. Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi. 5. University of North Carolina Project-Malawi, Lilongwe, Malawi; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 6. University of North Carolina Project-Malawi, Lilongwe, Malawi, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 7. Malawi Ministry of Health National Tuberculosis Programme, Lilongwe, Malawi.
Abstract
SETTING: Tuberculosis (TB) is a leading cause of childhood death. Patient-level data on pediatric TB in Malawi that can be used to guide programmatic interventions are limited. OBJECTIVE: To describe pediatric TB case burden, disease patterns, treatment outcomes, and risk factors for death and poor outcome. DESIGN: We conducted a retrospective cohort study utilizing routine data. Odds ratios (ORs) for factors associated with poor outcome and death were calculated using generalized estimating equations. RESULTS: Children represented 8% (371/4642) of TB diagnoses. The median age was 7 years (interquartile range 2.8-11); 32.8% (113/345) were human immunodeficiency virus (HIV) infected. Of these, 54.0% were on antiretroviral therapy (ART) at the time of anti-tuberculosis treatment (ATT) initiation, 21.2% started ART during ATT, and 24.8% had no documented ART. The treatment success rate was 77.3% (11.2% cured, 66.1% completed treatment), with 22.7% experiencing poor outcomes (9.5% died, 13.2% were lost to follow-up). Being on ART at the time of ATT initiation was associated with increased odds of death compared to beginning ART during treatment (adjusted OR 2.75, 95%CI 1.27-5.96). CONCLUSION: Children represent a small proportion of diagnosed TB cases and experience poor outcomes. Higher odds of death among children already on ART raises concerns over the management of these children. Further discussion of and research into pediatric-specific strategies is required to improve case finding and outcomes.
SETTING:Tuberculosis (TB) is a leading cause of childhood death. Patient-level data on pediatric TB in Malawi that can be used to guide programmatic interventions are limited. OBJECTIVE: To describe pediatric TB case burden, disease patterns, treatment outcomes, and risk factors for death and poor outcome. DESIGN: We conducted a retrospective cohort study utilizing routine data. Odds ratios (ORs) for factors associated with poor outcome and death were calculated using generalized estimating equations. RESULTS:Children represented 8% (371/4642) of TB diagnoses. The median age was 7 years (interquartile range 2.8-11); 32.8% (113/345) were human immunodeficiency virus (HIV) infected. Of these, 54.0% were on antiretroviral therapy (ART) at the time of anti-tuberculosis treatment (ATT) initiation, 21.2% started ART during ATT, and 24.8% had no documented ART. The treatment success rate was 77.3% (11.2% cured, 66.1% completed treatment), with 22.7% experiencing poor outcomes (9.5% died, 13.2% were lost to follow-up). Being on ART at the time of ATT initiation was associated with increased odds of death compared to beginning ART during treatment (adjusted OR 2.75, 95%CI 1.27-5.96). CONCLUSION:Children represent a small proportion of diagnosed TB cases and experience poor outcomes. Higher odds of death among children already on ART raises concerns over the management of these children. Further discussion of and research into pediatric-specific strategies is required to improve case finding and outcomes.
Authors: Susan D Emmett; Coleen K Cunningham; Blandina T Mmbaga; Grace D Kinabo; Werner Schimana; Mark E Swai; John A Bartlett; John A Crump; Elizabeth A Reddy Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Y D Mukadi; S Z Wiktor; I M Coulibaly; D Coulibaly; A Mbengue; A M Folquet; A Ackah; M Sassan-Morokro; D Bonnard; C Maurice; C Nolan; J K Kreiss; A E Greenberg Journal: AIDS Date: 1997-07-15 Impact factor: 4.177
Authors: Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen Journal: Lancet Date: 2014-03-24 Impact factor: 79.321
Authors: Chifumbe Chintu; Victor Mudenda; Sebastian Lucas; Andrew Nunn; Kennedy Lishimpi; Daniel Maswahu; Francis Kasolo; Peter Mwaba; Ganapati Bhat; Hiroshi Terunuma; Alimuddin Zumla Journal: Lancet Date: 2002-09-28 Impact factor: 79.321
Authors: Maria H Kim; Saeed Ahmed; W Chris Buck; Geoffrey A Preidis; Mina C Hosseinipour; Avni Bhalakia; Debora Nanthuru; Peter N Kazembe; Frank Chimbwandira; Thomas P Giordano; Elizabeth Y Chiao; Gordon E Schutze; Mark W Kline Journal: J Int AIDS Soc Date: 2012-07-11 Impact factor: 5.396
Authors: Aishatu L Adamu; Muktar H Aliyu; Najiba Aliyu Galadanci; Baba Maiyaki Musa; Muktar A Gadanya; Auwalu U Gajida; Taiwo G Amole; Imam W Bello; Safiya Gambo; Ibrahim Abubakar Journal: PLoS One Date: 2017-08-17 Impact factor: 3.240